Santidrian Antonio F, LeBoeuf Sarah E, Wold Erik D, Ritland Melissa, Forsyth Jane S, Felding Brunhilde H
Departments of Chemical Physiology and Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA.
DNA Repair (Amst). 2014 Nov;23:79-87. doi: 10.1016/j.dnarep.2014.08.006. Epub 2014 Sep 26.
NAD(+) metabolism is an essential regulator of cellular redox reactions, energy pathways, and a substrate provider for NAD(+) consuming enzymes. We recently demonstrated that enhancement of NAD(+)/NADH levels in breast cancer cells with impaired mitochondrial NADH dehydrogenase activity, through augmentation of complex I or by supplementing tumor cell nutrients with NAD(+) precursors, inhibits tumorigenicity and metastasis. To more fully understand how aberrantly low NAD(+) levels promote tumor cell dissemination, we here asked whether inhibition of NAD(+) salvage pathway activity by reduction in nicotinamide phosphoribosyltransferase (NAMPT) expression can impact metastasis and tumor cell adhesive functions. We show that knockdown of NAMPT, the enzyme catalyzing the rate-limiting step of the NAD(+) salvage pathway, enhances metastatic aggressiveness in human breast cancer cells and involves modulation of integrin expression and function. Reduction in NAMPT expression is associated with upregulation of select adhesion receptors, particularly αvβ3 and β1 integrins, and results in increased breast cancer cell attachment to extracellular matrix proteins, a key function in tumor cell dissemination. Interestingly, NAMPT downregulation prompts expression of integrin αvβ3 in a high affinity conformation, known to promote tumor cell adhesive interactions during hematogenous metastasis. NAMPT has been selected as a therapeutic target for cancer therapy based on the essential functions of this enzyme in NAD(+) metabolism, cellular redox, DNA repair and energy pathways. Notably, our results indicate that incomplete inhibition of NAMPT, which impedes NAD(+) metabolism but does not kill a tumor cell can alter its phenotype to be more aggressive and metastatic. This phenomenon could promote cancer recurrence, even if NAMPT inhibition initially reduces tumor growth.
NAD(+)代谢是细胞氧化还原反应、能量途径的重要调节因子,也是NAD(+)消耗酶的底物提供者。我们最近证明,通过增强复合物I或用NAD(+)前体补充肿瘤细胞营养物质,提高线粒体NADH脱氢酶活性受损的乳腺癌细胞中NAD(+)/NADH水平,可抑制肿瘤发生和转移。为了更全面地了解异常低的NAD(+)水平如何促进肿瘤细胞扩散,我们在此探讨通过降低烟酰胺磷酸核糖转移酶(NAMPT)表达来抑制NAD(+)补救途径活性是否会影响转移和肿瘤细胞黏附功能。我们发现,敲低NAMPT(催化NAD(+)补救途径限速步骤的酶)可增强人乳腺癌细胞的转移侵袭性,并涉及整合素表达和功能的调节。NAMPT表达降低与特定黏附受体的上调有关,特别是αvβ3和β1整合素,并导致乳腺癌细胞与细胞外基质蛋白的附着增加,这是肿瘤细胞扩散中的关键功能。有趣的是,NAMPT下调促使整合素αvβ3以高亲和力构象表达,已知这种构象在血行转移过程中促进肿瘤细胞黏附相互作用。基于NAMPT在NAD(+)代谢、细胞氧化还原、DNA修复和能量途径中的基本功能,它已被选为癌症治疗的靶点。值得注意的是,我们的结果表明,对NAMPT的不完全抑制(这会阻碍NAD(+)代谢但不会杀死肿瘤细胞)可改变其表型,使其更具侵袭性和转移性。即使NAMPT抑制最初会降低肿瘤生长,这种现象也可能促进癌症复发。